The present invention relates to pharmaceutical compositions based on antiinflammatory active ingredients and to the use thereof for the treatment of rheumatoid diseases. The compositions comprise lactalbumin hydrolysate or a fraction thereof. Substantially lower doses of the antiinflammatory drugs are thus possible than is conventionally necessary to achieve a particular antiinflammatory effect.

Chemical patent from PubChem database. Patent Number: AT-E399781-T1. Title: Novel Chemical Entity. Filing Date: 2004-10-11. Inventors: Anderson, Robert, Davis, Linda. Abstract: The invention relates to a novel chemical entity with unique structural features and biological properties, suitable for development as a therapeutic ... IPC Classifications: C07D, C07F, A61K. This patent covers 19 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

Chemical patent from PubChem database. Patent Number: AT-E399781-T1. Title: Novel Chemical Entity. Filing Date: 2004-10-11. Inventors: Anderson, Robert, Davis, Linda. Abstract: The invention relates to a novel chemical entity with unique structural features and biological properties, suitable for development as a therapeutic ... IPC Classifications: C07D, C07F, A61K. This patent covers 19 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

A pharmaceutical composition comprising a pharmaceutically effective amount of a pharmaceutically active substance and a pharmaceutically acceptable carrier including a cationic excipient, wherein said cationic excipient is a labile ester of betaine and a lipophilic alcohol having at least one primary hydroxyl group. Also, the use of a labile ester of betaine and a lipophilic alcohol having at least a primary hydroxyl group as a cationic excipient in a carrier for a pharmaceutical composition comprising a pharmaceutically active substance.

4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of rheumatoid arthritis. The invention also relates to a combination of the compound of the formula I or a pharmaceutically acceptable salt thereof with one or more disease modifying arthritis rheumatoid drugs (DMARDs).

The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, the present invention provides compositions comprising compounds of formula I for the treatment of metabolic syndrome, diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, other symptoms associated with hyperglycemia, and related disorders. Formula (I) wherein, R0 is (II), or (III) G1 is methylene or ethylene; L is a divalent linking group selected from —(C1-C4) alkylene-, —S—, —CH(OH)—, or —O—; A is methylene, —S—, —O—, or —NH—; and the other substituents are as defined in the claims.

Chemical patent from PubChem database. Patent Number: AT-E399765-T1. Title: Process for Preparing Therapeutic Agents. Filing Date: 2012-03-22. Inventors: Chen, Wei, Kumar, Raj, Williams, Sarah. Abstract: A process for preparing therapeutic agents is described, involving multiple synthetic steps with optimized reaction conditions. The process enables la... IPC Classifications: A61K, A61P, C07D. This patent covers 23 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, the present invention compositions containing these compounds for the treatment of metabolic syndrome, diabetes, hyperglycemia obesity, hypertension, hyperlipidemia, other symptoms associated with hyperglycemia, and related disorders. Formula I wherein G1 is methylene or ethylene; L is -(C1-C4)alkylene-, -S-, -CH(OH)-, or -O-; R0 is Formula II or Formula III and the other substituents are as defined in the claims.

The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, the present invention compositions containing these compounds for the treatment of metabolic syndrome, diabetes, hyperglycemia obesity, hypertension, hyperlipidemia, other symptoms associated with hyperglycemia, and related disorders. Formula I wherein G1 is methylene or ethylene; L is -(C1-C4)alkylene-, -S-, -CH(OH)-, or -O-; R0 is Formula II or Formula III and the other substituents are as defined in the claims.

Chemical patent from PubChem database. Patent Number: AT-E399536-T1. Title: Novel Pharmaceutical Composition. Filing Date: 2005-01-20. Inventors: Wilson, James, Brown, Patricia, Lee, David. Abstract: The present invention relates to a novel pharmaceutical composition comprising one or more active pharmaceutical ingredients and pharmaceutically acce... IPC Classifications: C07C, C07B, A61K. This patent covers 15 claims related to 5 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.